

Information For the User
Sitagliptin (50mg) + Glimepiride (2mg) + Metformin (1000mg) SR Tablet

Istalab GM 2/1000 Tablet

Brand Name: Istalab GM 2/1000 Tablet

Dosage Form: Tablet

Composition:

Each film-coated tablet contains:

- Sitagliptin IP 50 mg
- Glimepiride IP 2 mg
- Metformin Hydrochloride IP 1000 mg (Sustained Release)

Description:

Istalab GM 2/1000 Tablet is a fixed-dose combination of Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor; Glimepiride, a sulfonylurea; and Metformin Hydrochloride, a biguanide antidiabetic agent. It is indicated for the management of type 2 diabetes mellitus in patients inadequately controlled on dual therapy. The combination helps in achieving effective glycemic control by targeting multiple pathophysiological defects of diabetes.

Indications:

Indicated for the treatment of:

- Type 2 diabetes mellitus
- Patients inadequately controlled on dual antidiabetic therapy

It helps in controlling fasting and post-prandial blood glucose levels and improving overall glycemic stability.

Dosage & Administration:

Dosage should be as directed by the physician.

The tablet should be swallowed whole with water, preferably with meals.

Do not crush or chew the sustained-release component.

Regular monitoring of blood glucose levels is recommended.

Pharmacological Action:

- **Sitagliptin** inhibits the DPP-4 enzyme, increasing levels of incretin hormones, which enhance glucose-dependent insulin secretion and suppress glucagon release.
- **Glimepiride** stimulates insulin secretion from pancreatic beta cells, helping to lower blood glucose levels.
- **Metformin (Sustained Release)** reduces hepatic glucose production, improves insulin sensitivity, and decreases intestinal glucose absorption.

These complementary mechanisms provide synergistic and sustained glycemic control.

Side Effects:

Common side effects include gastrointestinal disturbances, hypoglycemia (primarily due to Glimepiride), headache, dizziness, and mild weakness.

Precautions & Warnings:

- Use with caution in patients with renal or hepatic impairment
- Monitor for hypoglycemia, especially in elderly patients
- Risk of lactic acidosis associated with Metformin in predisposed individuals
- Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis

Drug Interactions:

Concomitant use with insulin or other insulin secretagogues may increase the risk of hypoglycemia.

Caution with drugs that affect renal function or glucose metabolism.

Storage:

Store below 25°C in a cool, dry place.

Protect from light and moisture.

Keep out of reach of children.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for